Right posterior hypometabolism in Pisa syndrome of Parkinson's disease: A key to explain body schema perception deficit?
- PMID: 36989658
- DOI: 10.1016/j.parkreldis.2023.105371
Right posterior hypometabolism in Pisa syndrome of Parkinson's disease: A key to explain body schema perception deficit?
Abstract
Background: Pisa syndrome (PS) is a trunk postural abnormality in Parkinson's disease (PD). Its pathophysiology is still debated: peripheral and central mechanisms have been hypothesized.
Objective: To investigate the role of nigrostriatal dopaminergic deafferentation and of brain metabolism impairment in the onset PS in PD patients.
Methods: We retrospectively selected 34 PD patients who developed PS (PS+) and who had previously undergone dopamine transporter (DaT)-SPECT and/or brain F-18 fluorodeoxyglucose PET (FDG-PET). PS + patients were divided considering leaning body side in left ((l)PS+) or right ((r)PS+). DaT-SPECT specific-to-non-displaceable binding ratio (SBR) of striatal regions (BasGan V2 software) were compared between 30 PS+ and 60 PD patients without PS (PS-) as well as between 16 (l)PS+ and 14 (r)PS + patients. Voxel-based analysis (SPM12) was used to compare FDG-PET among 22 PS+, 22 PS- and 42 healthy controls (HC) and between 9 (r)PS+ and 13 (l)PS+.
Results: No significant DaT-SPECT SBR differences were found between PS+ and PS- groups or between (r)PD+ and (l)PS + subgroups. Compared to HC, significant hypometabolism in PS+ was found in bilateral temporal-parietal regions, mainly in the right hemisphere, whereas the right Brodmann area 39 (BA39) was relatively hypometabolic both in the (r)PS+ and in the (l)PS+. BA39 and bilateral posterior cingulate cortex were significantly hypometabolic in PS + than in PS- group.
Conclusions: As a hub of the network supervising the body schema perception, the involvement of the right posterior hypometabolism supports the hypothesis PS is a result of a somatosensory perceptive deficit rather than a nigrostriatal dopaminergic unbalance.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest Matteo Pardini receives research support from Novartis and Nutricia, received fees from Novartis, Merck and Biogen. Silvia Morbelli received speaking honoraria from G.E. healthcare. Flavio Nobili received fees from BIAL for consultation, from G.E. healthcare for teaching talks, from Roche for board participation. Dario Arnaldi received fees from Fidia for lectures and board participation. Federico Massa received a speaker honorarium from Roche Diagnostics. All other authors report no competing interests.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources